Nykredit A S Buys Shares of 41,734 Biogen Inc. $BIIB

Nykredit A S purchased a new stake in shares of Biogen Inc. (NASDAQ:BIIB) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 41,734 shares of the biotechnology company’s stock, valued at approximately $9,017,000.

Several other institutional investors have also modified their holdings of the company. Bell Investment Advisors Inc acquired a new position in Biogen during the 2nd quarter valued at about $27,000. Reflection Asset Management acquired a new stake in shares of Biogen in the fourth quarter valued at approximately $25,000. Root Financial Partners LLC raised its holdings in shares of Biogen by 198.4% during the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 123 shares during the last quarter. MV Capital Management Inc. acquired a new position in shares of Biogen during the fourth quarter worth approximately $34,000. Finally, Strive Financial Group LLC acquired a new position in shares of Biogen during the fourth quarter worth approximately $35,000. Institutional investors own 87.93% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Weiss Ratings cut Biogen from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, August 12th. Evercore started coverage on shares of Biogen in a research note on Friday, May 15th. They set an “outperform” rating on the stock. HC Wainwright upped their price target on shares of Biogen from $237.00 to $251.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Wall Street Zen cut shares of Biogen from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Finally, Canaccord Genuity Group raised their price objective on shares of Biogen from $245.00 to $248.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $228.50.

Biogen Price Performance

NASDAQ:BIIB opened at $220.83 on Friday. The business’s 50-day moving average price is $209.53 and its 200 day moving average price is $196.62. The firm has a market cap of $32.63 billion, a P/E ratio of 39.08, a PEG ratio of 2.44 and a beta of 0.17. Biogen Inc. has a 52-week low of $135.39 and a 52-week high of $225.80. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, topping the consensus estimate of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The firm had revenue of $2.74 billion for the quarter, compared to analysts’ expectations of $2.46 billion. During the same period in the previous year, the business earned $5.47 earnings per share. Biogen’s revenue for the quarter was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, sell-side analysts predict that Biogen Inc. will post 12.39 earnings per share for the current fiscal year.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Long-term Dravet syndrome data support zorevunersen. Biogen and Stoke Therapeutics reported four-year Phase 1/2a extension data showing durable seizure reductions, including reductions in severe seizure types associated with sudden unexpected death in epilepsy, as well as continued improvements in cognition, behavior and quality of life. The results strengthen the potential for zorevunersen to become a disease-modifying treatment, though it remains investigational. Stoke and Biogen unveil long-term zorevunersen data
• Positive Sentiment: LEQEMBI gained a major China regulatory approval. China’s National Medical Products Administration approved the once-weekly subcutaneous autoinjector formulation of LEQEMBI for initiation treatment in early Alzheimer’s disease. At-home dosing could improve patient convenience, reduce infusion-center burdens and broaden adoption in a large and growing market. Eisai leads development and commercialization, with Biogen sharing economics under their collaboration. Biogen and Eisai announce China LEQEMBI approval
• Positive Sentiment: U.S. patients can now access weekly at-home LEQEMBI injections. Biogen and Eisai launched LEQEMBI IQLIK in the United States for eligible early Alzheimer’s patients, offering initiation and maintenance treatment through a pre-filled syringe or autoinjector. The new delivery option may lower barriers to treatment and support future product demand.
• Neutral Sentiment: Investors are assessing valuation after a strong rally. A valuation analysis argued that BIIB could be materially below estimated discounted-cash-flow value, but also noted that earnings-based multiples make the shares appear expensive. This conflicting signal may be contributing to caution after the stock’s substantial one-year gain.
• Negative Sentiment: Execution and safety risks remain. Zorevunersen’s data are from open-label early-stage studies and require confirmation in later trials. LEQEMBI’s subcutaneous formulation also carries injection-related reactions and still requires MRI monitoring for amyloid-related imaging abnormalities, potentially limiting uptake.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.